You have no items in your shopping cart.
On Promotion
Elisa Kits Promotion 1
Products on Sale 0
Category
Antibodies 6516
Proteins and Peptides 1531
Small Molecules 324
Tools 79
Assays and Kits 71
Species Host
Rabbit 4935
Mouse 891
Human 160
Goat 29
E. coli 28
Mammal 24
Plant 8
Camelus 6
Gallus 1
Tested Applications
IF 3254
WB 2350
FC 1851
ELISA 1283
IHC-P 1005
ICC 603
IHC-Fr 494
IHC 97
Blocking 59
EIA 54
NeA 53
DOT 38
Kinetics 34
IP 23
LF 16
SDS-PAGE 12
GICA 11
CLIA 8
FA 8
MS 8
Functional Studies 7
IA 7
In vivo 6
Crystallography 5
Control 4
FACS 3
RNA-I 3
AP 1
Array 1
ICA 1
IH 1
Reactivity
Human 4695
Mouse 2362
Rat 1759
Virus 877
Other 61
Zebrafish 58
Rabbit 57
Guinea pig 29
Gallus 28
Bovine 26
Hamster 7
Monkey 5
E. coli 3
Primate 3
Canine 2
Porcine 2
All 1
Feline 1
Goat 1
Sheep 1
Predicted Reactivity
Porcine 1919
Canine 1771
Bovine 1734
Rat 1655
Mouse 1472
Rabbit 1226
Equine 1036
Sheep 763
Gallus 602
Human 564
Guinea 321
Pig 321
Virus 157
Zebrafish 68
Mammal 55
Other 30
Primate 27
Insect 23
Hamster 19
Monkey 10
Yeast 8
Drosophila 6
C 4
Elegans 4
Conjugation
Unconjugated 2662
Biotin 257
HRP 243
AP 179
FITC 153
APC 150
Cy3 149
PE 148
APC/Cy7 137
APC/Cy5.5 136
BF350 136
Cy5.5 136
PerCP 136
PerCP/Cy5.5 136
RBITC 136
BF405 135
BF750 135
Cy7 135
BF680 134
Cy5 134
BF555 133
BF594 132
BF647 130
BF488 125
PE/Cy7 112
PE/Cy5 111
PE/Cy5.5 111
PerCP/Cy7 67
BF700 14
IRDye800 14
iFluor647 14
Pacific Blue 11
AE 7
Clonality
Polyclonal 4926
Monoclonal 1302
Recombinant 278
Matched Antibody
Yes 0
No 8521
Featured Product
Yes 899
Has Publications
Yes 25
No 8496
Search results for: 'sars'
98.00%
26.55 kDa (predicted); 34.86 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1(N354D)) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro. Predicted N terminal: Arg 319
C-His
20 μg98.00%
28.49 kDa (predicted); 36.21 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations E484K, K417T, N501Y) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant P.1) which emerged in the Brazil. Predicted N terminal: Ser
C-His-Avi
20 μg98.00%
28.49 kDa (predicted); 37.69 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation N501Y) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.7) which emerged in the UK. Predicted N terminal: Ser
C-His-Avi
20 μg98.00%
28.43 kDa (predicted); 36.02 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations L452R, T478K) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.2) which emerged in the India. Predicted N terminal: Arg 319
C-His-Avi
20 μg98.00%
28.4 kDa (predicted); 35.88 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations L452R, E484Q) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617, B.1.617.1, B.1.617.3) which emerged in the India. Predicted N terminal: Arg 319
C-His-Avi
20 μg98.00%
77.95 kDa (predicted); 90.57 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations (HV69-70, Y145)deletion, N501Y, A570D, D614G, P681H) (Met1-Arg685) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.7) which emerged in the UK. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
77.84 kDa (predicted); 120.35 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations (LAL242-244)deletion, L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G) (Met1-Arg685) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.351) which emerged in the South Africa. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
78.43 kDa (predicted); 116 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations T19R, G142D, L452R, E484Q, D614G, P681R) (Met1-Arg685) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.3) which emerged in the India. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
28.48 kDa (predicted); 36.17 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation K417N, E484K, N501Y) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.351) which emerged in the South Africa. Predicted N terminal: Ser
C-His-Avi
20 μg98.00%
51.89 kDa (predicted); 58.07 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation L452R, T478K) (Arg319-Phe541) was expressed with the Fc region of human IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.2) which emerged in the India. Predicted N terminal: Arg 319
C-Fc
100 μg